{"id":958870,"date":"2026-05-06T08:15:19","date_gmt":"2026-05-06T12:15:19","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/"},"modified":"2026-05-06T08:15:19","modified_gmt":"2026-05-06T12:15:19","slug":"orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/","title":{"rendered":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">\n          <em>Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (\u201cBACKBEAT Trial\u201d) evaluating Atrioventricular Interval Modulation Therapy (\u201cAVIM Therapy\u201d) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic<\/em>\n        <\/li>\n<li style=\"margin-bottom:8pt;text-align:justify\">\n          <em>This payment, together with $15 million received from Ligand\u00a0<\/em>and <em>announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements<\/em><\/li>\n<\/ul>\n<p align=\"justify\">NEW HOPE, Pa., May  06, 2026  (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (\u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million investment from Medtronic, plc. (NYSE: MDT, \u201cMedtronic\u201d) pursuant to the previously disclosed strategic financing agreement. The funding represents the completion of a scheduled tranche under the agreement, as well as Medtronic\u2019s continued support for the BACKBEAT Trial for AVIM Therapy, Orchestra BioMed\u2019s global pivotal trial evaluating its patented investigational treatment for uncontrolled hypertension in pacemaker-indicated patients.<\/p>\n<p align=\"justify\">\n        <strong>Robert C. Kowal, M.D., Ph.D., Vice President and General Manager of Cardiac Pacing Therapies within the Medtronic Cardiac Rhythm Management operating unit<\/strong>, commented, \u201cThe completion of this investment aligns with the strong clinical trial enrollment we\u2019ve seen in the BACKBEAT Trial for AVIM Therapy. Our collaboration with Orchestra BioMed opens the door to bringing the benefits of pacing therapy to patients with needs beyond traditional rhythm management, offering the potential to treat hypertension and hypertensive heart disease.\u201d<\/p>\n<p align=\"justify\">\u201cMedtronic has been an excellent strategic collaborator for the AVIM Therapy program, and this funding further reinforces our long-term alignment under our strategic collaboration agreement,\u201d said <strong>David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed<\/strong>. \u201cThis funding and the structure of the agreement align capital investments with key regulatory and commercialization objectives as we and Medtronic continue our shared work to complete the BACKBEAT Trial and ultimately deliver AVIM Therapy to pacemaker-indicated patients with uncontrolled hypertension despite medication.\u201d<\/p>\n<p align=\"justify\">The $20 million payment fulfills Medtronic\u2019s previously disclosed commitment in exchange for a secured subordinated promissory note convertible to capped prepaid revenue share. As previously disclosed, the note automatically converts to a prepaid revenue share upon U.S. Food and Drug Administration (\u201cFDA\u201d) approval of AVIM Therapy. The prepaid revenue share will be credited back to Medtronic at a low double-digit percentage of actual AVIM Therapy revenue share paid to Orchestra BioMed, up to $40 million in cumulative revenue share.<\/p>\n<p align=\"justify\">This payment, together with a $15 million planned revenue interest purchase tranche payment from Ligand Pharmaceuticals announced separately, completes a total of $35 million in strategic capital received on May 1, 2026 under previously disclosed agreements.<\/p>\n<p align=\"justify\">\n        <strong>About Orchestra BioMed <\/strong><br \/>\n        <br \/>Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company\u2019s two flagship product candidates &#8211; Atrioventricular Interval Modulation (AVIM) Therapy and Virtue<sup>\u00ae<\/sup>\u00a0Sirolimus AngioInfusion\u2122 Balloon (Virtue SAB) &#8211; are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered by a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world and the global leader in cardiac pacing therapies, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designations for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind non-coated drug delivery angioplasty balloon system designed to deliver a large liquid dose of proprietary extended-release formulation of sirolimus, SirolimusEFR\u2122, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary in-stent restenosis, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=J7z-t66_fpB31dsrDU_2nx5oLWVBGPg0JmiO1c2uAlsRSV7xnpOQuSMZeX0-kwguE2ON3cg4J4PEvvyfByDd4ykVgDQ--iqVqc1KbSuja8hPv3FRQNmlgj3o0IDVi2d3mJNmSgWrO0HNNMc4eZBrV1pTA2JcM_oeKq1uzsQVCjeEMiz58D--bEI8bTrCxSRFG0vDD6SOI0_Dzik5Je9xF93oUcfSTSx9NFtlxIUq-EBE5IO20ZM1N0vLm8zgkEzZVn8P5tcWCDoOvHtQVSzSRw==\" rel=\"nofollow\" target=\"_blank\"><u>www.orchestrabiomed.com<\/u><\/a>, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=re46e7nbhVL2ZtCCGQszG17QMLDrr2QfsMYUYSpiXtxEUvjC83htMbOJRLYT3zCRyJgKu60QOB3iALRdj6Fv1gehQAk5-3Ld2HASFo8-90vWu4TrCC_54BxVpizyl5HHhqYTsqX5nJfiq7K2TTjKUAZEU5Yx_J1HVLBFVZJhW6miNaLry-r25YyAJwqCy21gXY9yLqzE6S3uMmDVj0SOWarumcd_zjYU2Ey--sgd90n6C4znaWKLzg-Wqp3iggTtpa2ilDKdAFKujliJoG7T-w==\" rel=\"nofollow\" target=\"_blank\"><u>LinkedIn<\/u><\/a>.<\/p>\n<p align=\"justify\">\n        <strong>About AVIM Therapy<\/strong><br \/>\n        <br \/>AVIM Therapy is an investigational therapy compatible with standard dual-chamber pacemakers designed to substantially and persistently lower blood pressure. It has been evaluated in pilot studies in patients with hypertension who are also indicated for a pacemaker. MODERATO II, a double-blind, randomized pilot study, showed that patients treated with AVIM Therapy experienced net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure (aSBP) and 12.3 mmHg in office systolic blood pressure (oSBP) at six months when compared to control patients. In addition to reducing blood pressure, clinical results using AVIM Therapy demonstrate improvements in cardiac function and hemodynamics. The BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) global pivotal trial is evaluating the safety and efficacy of AVIM Therapy in lowering blood pressure in patients who have systolic blood pressure above target despite anti-hypertensive medication and who are indicated for or have recently received a dual-chamber cardiac pacemaker. AVIM Therapy has been granted two Breakthrough Device Designations by the FDA for the treatment of uncontrolled hypertension in patients who have increased cardiovascular risk.<\/p>\n<p>\n        <strong>About Virtue SAB<\/strong><br \/>\n        <br \/>Virtue SAB is designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR\u2122 through a non-coated microporous AngioInfusion\u2122 Balloon that protects the drug in transit to consistently deliver a large liquid dose overcoming certain limitations of drug-coated balloons. SirolimusEFR delivered by Virtue SAB has been shown in published preclinical series involving hundreds of arterial deliveries to achieve sustained tissue levels well above the known required therapeutic tissue concentration for inhibiting restenosis (1 ng\/mg tissue) for the entire critical healing period of approximately 30 days. Virtue SAB demonstrated positive three-year clinical data in coronary ISR in the SABRE study, a multi-center prospective, independent core lab-adjudicated pilot clinical study of 50 patients conducted in Europe. Virtue SAB has been granted Breakthrough Device Designation by the FDA for specific indications relating to coronary ISR, coronary small vessel disease and peripheral artery disease below-the-knee.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements <\/strong><br \/>\n        <br \/>\n        <em>Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements relating to the initiation, enrollment, timing, implementation and design of the Company\u2019s ongoing pivotal trials, realizing the clinical and commercial value of AVIM Therapy and Virtue SAB, the potential safety and efficacy of the Company\u2019s product candidates, the potential benefits of <\/em>Breakthrough Device Designation<em>, and the ability of the Company\u2019s partnerships to accelerate clinical development. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the Company\u2019s management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from assumptions. Many actual events and circumstances are beyond the control of the Company. These forward-looking statements are subject to a number of risks and uncertainties, including changes in domestic and foreign business, market, financial, political, and legal conditions; risks related to regulatory approval of the Company\u2019s commercial product candidates and ongoing regulation of the Company\u2019s product candidates, if approved; the timing of, and the Company\u2019s ability to achieve expected regulatory and business milestones; the impact of competitive products and product candidates; and the risk factors discussed under the heading \u201cItem 1A. Risk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on March 12, 2026.<\/em><\/p>\n<p align=\"justify\">\n        <em>The Company operates in a very competitive and rapidly changing environment. New risks emerge from time to time. Given these risks and uncertainties, the Company cautions against placing undue reliance on these forward-looking statements, which only speak as of the date of this press release. The Company does not plan and undertakes no obligation to update any of the forward-looking statements made herein, except as required by law.<\/em>\n      <\/p>\n<p align=\"justify\">\n        <strong>Investor Contact:<\/strong><br \/>\n        <br \/>Silas Newcomb<br \/>Orchestra BioMed<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3rnGpbQ6aJqVt3eHS0bJzM8q7OOUX3XyCB8NFrWugqWmlm9OI1og141D0WQaNsYFmRmvsTjwixLao8r_lnRbs1irwA7IUAl3XV8FrZmL6gZhXds95vaEE5pUzy_S0O8L\" rel=\"nofollow\" target=\"_blank\"><u>Snewcomb@orchestrabiomed.com<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Kelsey Kirk<br \/>Orchestra BioMed<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=lpUykws1H9vW0ydXKnnrTLaqGKBosyrn3vhxPmX3Ylxh2QO-WeCRo2Jim2MnFr21h5NwTU1QN985whoC02quVqWWakkatLm9CCJPBxeh-Rwlws9Bn_RIgkDu7ptGIWlH\" rel=\"nofollow\" target=\"_blank\"><u>kkirkellis@orchestrabiomed.com<\/u><\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTYwODBhY2UtNzkyNi00M2JmLThlOGItZTQwYjUxMmFmMTIzLTEyMDU1NzItMjAyNi0wNS0wNi1lbg==\/tiny\/Orchestra-BioMed-Holdings-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (\u201cBACKBEAT Trial\u201d) evaluating Atrioventricular Interval Modulation Therapy (\u201cAVIM Therapy\u201d) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand\u00a0and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (\u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958870","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (\u201cBACKBEAT Trial\u201d) evaluating Atrioventricular Interval Modulation Therapy (\u201cAVIM Therapy\u201d) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand\u00a0and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (\u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million &hellip; Continue reading &quot;Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-06T12:15:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement\",\"datePublished\":\"2026-05-06T12:15:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/\"},\"wordCount\":1466,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/\",\"name\":\"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\",\"datePublished\":\"2026-05-06T12:15:19+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/","og_locale":"en_US","og_type":"article","og_title":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk","og_description":"Payment fulfills previously disclosed funding commitment of $20 million and supports planned completion of the BACKBEAT Global Pivotal Trial (\u201cBACKBEAT Trial\u201d) evaluating Atrioventricular Interval Modulation Therapy (\u201cAVIM Therapy\u201d) in patients with uncontrolled hypertension and an indication for a pacemaker as part of the strategic collaboration between Orchestra BioMed and Medtronic This payment, together with $15 million received from Ligand\u00a0and announced separately, represents a total of $35 million in strategic capital received under previously disclosed agreements NEW HOPE, Pa., May 06, 2026 (GLOBE NEWSWIRE) &#8212; Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (\u201cOrchestra BioMed\u201d or the \u201cCompany\u201d), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced the receipt of a $20 million &hellip; Continue reading \"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-06T12:15:19+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement","datePublished":"2026-05-06T12:15:19+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/"},"wordCount":1466,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/","name":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=","datePublished":"2026-05-06T12:15:19+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcxMzkyMyM3NTg1NTI5IzIxOTQwMTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/orchestra-biomed-receives-20-million-payment-from-medtronic-under-previously-announced-financing-agreement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958870","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958870"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958870\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958870"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958870"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958870"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}